CoChat

Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England

Open access

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index; 6 of the 70 sources its claims cite were checked for support.

Abstract

BACKGROUND: Injection site infections among injecting drug users (IDUs) have been associated with serious morbidity and health service costs in North America. This study explores the frequency, factors and costs associated with injection site infections among IDUs in England. METHODS: Unlinked-anonymous survey during 2003/05 recruiting IDUs from community settings at seven locations across England. Self-reported injecting practice, symptoms of injection site infections (abscess or open wound) and health service utilisation data were collected using a questionnaire, participants also provided dried blood spot samples (tested for markers blood borne virus infections). Cost estimates were obtained by combining questionnaire data with information from national databases and the scientific literature. RESULTS: 36% of the 1,058 participants reported an injection site infection in the last year. Those reporting an injection site infection were more likely to be female and aged over 24, and to have: injected into legs, groin, and hands in last year; injected on 14 or more days during the last four weeks; cleaned needles/syringes for reuse; injected crack-cocaine; antibodies to hepatitis C; and previously received prescribed substitute drug. Two-thirds of those with an injection site infection reported seeking medical advice; half attended an emergency department and three-quarters of these reported hospital admission. Simple conservative estimates of associated healthcare costs range from pound 15.5 million per year to as high as pound 30 million; though if less conservative unit costs assumptions are made the total may be much higher (pound 47 million). The vast majority of these costs are due to hospital admissions and the uncertainty is due to little data on length of hospital stays. CONCLUSION: Symptoms of injection site infections are common among IDUs in England. The potential costs to the health service are substantial, but these costs need more accurate determination. Better-targeted interventions to support safer injection need to be developed and evaluated. The validity of self-reported symptoms, and the relationship between symptoms, infection severity, and health seeking behaviour require further research.

Overview

CoChat Summary

TL;DR

In a 2003/05 national multi-site survey of 1,058 injecting drug users in England, 36% reported an injection site infection (abscess or open wound) in the past year. Associated healthcare costs were conservatively estimated at £15.5–30 million annually, with hospital admissions driving most of the cost.

Key findings

  • 36% (385/1,058) reported an injection site infection in the previous year. In multivariate analysis, factors associated included female gender (aOR 1.7, 95% CI 1.2–2.4), age 25+ (e.g. 30–34 aOR 2.0, 1.3–3.2), injecting into leg (aOR 2.2, 1.6–3.1), groin (aOR 1.4, 1.1–1.9), or hand (aOR 1.9, 1.3–2.6), injecting on 14–27 days in the last 4 weeks (aOR 1.8, 1.2–2.9), cleaning needles/syringes for reuse (aOR 1.5, 1.1–2.1), crack-cocaine injection (aOR 1.5, 1.1–2.0), anti-HCV positivity (aOR 1.5, 1.1–2.0), and previously receiving prescribed substitute drug (aOR 1.7, 1.3–2.4).
  • Among those reporting an infection, 68% (260/382) sought health care; 47% (180/381) attended an emergency department, and 78% (140/180) of those attending an emergency department were admitted to hospital.
  • Annual cost estimates ranged from at least £19.2 million (low unit costs per hospital stay, 140,000 IDUs) to £30.5 million (high unit costs per hospital stay, 140,000 IDUs); using daily costs, estimates were at least £15.5 million for a 2-day stay and £20.6 million for a 4-day stay. Table 4 totals reached £46.9 million for 215,000 IDUs with high unit costs. Hospital admissions made up over 88% of total cost estimates.
  • The authors estimate over 30,000 IDUs seek health care for injection site infections each year in England, with at least 18,500 admitted to hospital.

Methods

  • Unlinked-anonymous community-recruited survey conducted autumn 2003–summer 2005 at seven broadly representative locations in England; 1,058 participants who had injected in the preceding 28 days completed a questionnaire on demographics, injecting practice, symptoms of injection site infection, and health service use, and provided dried blood spot samples tested for anti-HCV, anti-HBc, and anti-HIV.
  • Univariable χ² analyses followed by forward stepwise logistic regression identified factors associated with reporting an injection site infection and with seeking health care for it.
  • Cost estimation combined questionnaire data with NHS reference costs 2005–06 and Unit Costs of Health and Social Care 2006, scaled to IDU population estimates of 140,000 (opiate/crack injectors) and 215,000 (all IDUs), assuming one infection episode per IDU per year.

Limitations

  • Stated by the paper: self-reported symptoms were used, though prior studies show good concordance with clinical diagnosis; sampling may over-represent high-risk IDUs who use needle exchanges and other recruitment settings, so cost estimates could be overestimates; cost estimates were conservative, assuming only one care episode per year, lacking UK-specific length-of-stay data, and excluding high-dependency or other high-cost care.
  • Evident from the text: the cross-sectional design cannot establish causality between associated factors and injection site infections; health service use and cost inputs rely on self-report and external unit-cost assumptions, making the economic estimates exploratory.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1471-2334-8-120

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

5 Valid · 0 Not valid · 31 Not checked · 52 Own results and interpretations

48 more claims

Create a free account to see all 88 claims and to verify the 64 references still open.

See all claims — free account
  • Probably not a substantial claim. 28
  • It may state two separate claims as one. 15

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 35 references

Research works printed but not linked: 4

  1. Kearns AM Rathmann IR Holmes A Pitt TL Cookson BD An unusual clone of MRSA causing infection in injecting drug users J Infect 2004 49 49 50
  2. Akbulut D Dennis J Gent M Grant KA Hope V Ohai C McLauchlin J Mithani V Mpamugo O Ncube F Outbreak report: Wound botulism in injectors of illicit drugs: upsurge in cases in England during 2004 EuroSurveillance Monthly 2005 10
  3. National Health Service NHS reference costs 2005–06 2006 London: Department of Health
  4. Curtis L Netten A Unit costs of Health and Social Care 2006 Personal Social Services Research Unit Canterbury: University of Kent

Cited by

See all 112

Metadata

Authors
Hope, V., Kimber, J., Vickerman, P., Hickman, M., & Ncube, F.
Affiliations
  • UNSW Sydney (AU)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Bristol (GB)
Corresponding author
Hope, Vivian
Venue
BMC Infectious Diseases
Published
2008-09-18
Volume
8
Issue
1
Pages
120-120
ISSN
1471-2334 (ISSN-L)
OpenAlex
W2068816858
Cited by
112
References
36
Citations by year
2026: 1 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 10 · 2018: 6 · 2017: 6 · 2016: 7 · 2015: 9 · 2014: 7 · 2013: 5 · 2012: 4
FWCI
4.47
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • BMC Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Explore Bristol Research (publishedVersion)
  • Liverpool John Moores University (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Australian Government
  • National Institute for Health and Care Research
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
  • Social Sciences › Cultural Studies › Tattoo and Body Piercing Complications
Keywords
injection site infection, people who inject drugs, health care costs, needle reuse, hepatitis C, crack cocaine, hospitalization, health care utilization, self-reported symptoms, risk factors
MeSH terms
Adolescent, Adult, Age Factors, Aged, Ambulatory Care, Bacterial Infections, England, Female, Hospitalization, Humans, Infections, Male, Middle Aged, Office Visits, Surveys and Questionnaires, Sex Factors, Substance Abuse, Intravenous, Health Care Costs, Drug Users

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. https://app.cochat.ai/papers/10.1186/1471-2334-8-120
The paper
Hope, V., Kimber, J., Vickerman, P., Hickman, M., & Ncube, F. (2008). Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-8-120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.